Related Experiment Videos
Reduction in transfusion requirements with early epoetin alfa treatment in pediatric patients with solid tumors: a
Martina Kronberger1, Gustav Fischmeister, Ulrike Poetschger
1St. Anna Children's Hospital, Vienna, Austria.
Insights
Epoetin alfa effectively reduced red blood cell and platelet transfusion needs in pediatric cancer patients undergoing chemotherapy. This study found no drug-related adverse events, suggesting a favorable safety profile for epoetin alfa in this population.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Chemotherapy in pediatric cancer patients often leads to anemia and thrombocytopenia.
- Epoetin alfa is a biologic agent used to stimulate red blood cell production.
Purpose of the Study:
- To evaluate the efficacy and safety of epoetin alfa in pediatric cancer patients receiving chemotherapy.
- To assess the impact of epoetin alfa on transfusion requirements and hemoglobin levels.
Main Methods:
- A single-center, case-control study involving 37 pediatric cancer patients treated with epoetin alfa and 37 untreated controls.
- Epoetin alfa was administered at 150 IU/kg or 300 IU/kg three times weekly for 28 weeks.
- Outcomes included red blood cell and platelet transfusion requirements, time to first transfusion, and hemoglobin levels.
Main Results:
- Epoetin alfa treatment was associated with significantly lower overall red blood cell (p = .007) and platelet transfusion requirements (p = .010).
- Kaplan-Meier analysis showed a significantly longer mean time to first red blood cell transfusion in the epoetin alfa group (p = .0004).
- Mean hemoglobin levels were maintained near baseline in the epoetin alfa group throughout the study, with no drug-related adverse events observed.
Conclusions:
- Epoetin alfa is effective in reducing transfusion needs in pediatric cancer patients undergoing chemotherapy.
- The drug demonstrated a favorable safety profile with no observed drug-related adverse events.
- Epoetin alfa may be a valuable supportive care option for pediatric oncology patients experiencing chemotherapy-induced anemia.
Abstract:
In a single-center, case-control study the authors evaluated the efficacy and safety of epoetin alfa in pediatric cancer patients receiving platinum- or nonplatinum-based chemotherapy. Thirty-seven patients with solid tumors received epoetin alfa 3 times weekly at a dose of 150 IU/kg (hemoglobin [Hb] > or = 12 g/dL and < or = 16 g/dL) or 300 IU/kg (Hb) < 12 g/dL) for 28 weeks. Data from treated patients were compared to data from 37 untreated control patients. Significant between-group differences in favor of the epoetin alfa-treated Patients were observed in overall red blood cell transfusion requirements (p = .007) and overall platelet transfusion requirements (p = .010). Additionally, significant between-group differences favoring epoetin alfa were seen by Kaplan-Meier plots, estimating mean time to first red blood cell transfusion (p = .0004). Mean Hb (g/dL) was maintained at baseline levels in the epoetin alfa group for most of the course of the study. No drug-related adverse events were seen in epoetin alfa-treated patients.